Anmeldung erfolgt in Kürze...
Details werden geladen...
BIO 2026: Biopharma dealmakers seek to protect ‘premium pricing’ from Trump’s MFN policy - BioSpace
With drug pricing now embedded in U.S. policy, business development teams in biotech and pharma are changing the way they strike deals, including acknowledging policy uncertainties with renegotiation clauses.